严重 COVID-19 中的血栓栓塞并发症：当前抗血栓策略和未来展望。
Thromboembolic Complications in Severe COVID-19: Current Antithrombotic Strategies and Future Perspectives.
机构信息
Facultad de Medicina, Universidad Autonoma Bucaramanga, Bucaramanga, Colombia.
Department of Interventional Cardiology, Del Sol Medical Center, El Paso, TX 79925, United States.
出版信息
Cardiovasc Hematol Disord Drug Targets. 2021;21(1):23-29. doi: 10.2174/1871529X21666210315123347.
The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS- CoV-2) is our latest pandemic and has turned out to be a global public health crisis. One of the special characteristics of this disease is that it may predispose patients to thrombotic disease both in the venous and arterial circulation. We review arterial and venous thromboembolic complications in patients with COVID-19, epidemiology, pathogenesis, hematologic biomarkers, and current antithrombotic strategies. Future perspectives and clinical trials are ongoing to determine the best thromboprophylaxis strategies in the hospitalized patients with severe COVID-19.
由严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）引起的 2019 年冠状病毒病（COVID-19）是我们最近的一次大流行，已成为全球公共卫生危机。这种疾病的一个特殊特征是，它可能使静脉和动脉循环中的患者易患血栓性疾病。我们回顾了 COVID-19 患者的动脉和静脉血栓栓塞并发症、流行病学、发病机制、血液生物标志物和当前的抗血栓形成策略。正在进行未来的展望和临床试验，以确定严重 COVID-19 住院患者最佳的血栓预防策略。
Zotero 插件